When private equity firms look at behavioral health acquisition markets, they typically start with the obvious: major metros, high population density, strong commercial payer mix. What the data actually shows is more counterintuitive.

We scored 27,818 behavioral health facilities across all US counties using three dimensions — provider supply gap, commercial payer concentration, and PE platform penetration. The markets that score highest aren't the obvious ones.

What "Underserved" Actually Means for PE

In PE acquisition context, underserved doesn't simply mean rural or low-income. It means a market where three conditions converge: meaningful unmet demand, limited existing PE platform presence, and a commercial payer mix that can support the revenue multiples required for a viable roll-up.

A county with 40% Medicaid concentration and no PE platforms may look like whitespace on the surface. But entering a market where the majority of revenue is tied to state Medicaid rates — which face significant pressure through 2027–2028 — creates a different risk profile than a market where commercial insurance is dominant.

The Scoring Methodology

Our Acquisition Score (0–100) weights three factors: Demand (35%), reflecting population need and growth; Fragmentation (35%), reflecting solo operator ratios and HRSA shortage designations; and Market Quality (30%), reflecting payer mix, clinical quality signals, and multi-location density.

The Top 10 Markets

The highest-scoring behavioral health acquisition markets in our national dataset share a common profile: mid-sized metros (not megacities), growing populations in the 25–44 demographic, commercial insurance rates above 55%, and zero or minimal existing PE platform presence.

What These Markets Have in Common

Every market in the top 10 has a solo operator ratio above 73% — meaning fewer than 1 in 4 behavioral health providers are affiliated with a group or platform. That fragmentation is the acquisition opportunity. It means there are dozens of independent operators in each market who are potential platform targets or add-ons.

The commercial payer mix floors in these markets (all above 59%) provide the revenue quality that PE roll-up models require. Markets with lower commercial concentration carry meaningful exposure to the Medicaid rate changes anticipated under federal budget legislation through 2027–2028.

The Medicaid Risk Factor

Our Medicaid Exposure Risk Score — a proprietary metric included in the full AcuiteIQ Behavioral Health report — flags markets where facilities carry 60%+ Medicaid revenue concentration. These markets are excluded from the top 10 above regardless of fragmentation score, because the revenue risk profile makes them substantially harder to underwrite at current multiples.

PE firms that entered high-Medicaid behavioral health markets in 2022–2023 are now facing that risk directly. The markets above are selected in part because they don't carry that exposure.

Dental is the most active PE vertical in healthcare by deal volume — 161 transactions in 2024, more than any other specialty. There are currently 130+ PE-backed DSOs operating across the US. And yet the consolidation wave is nowhere near finished.

Why Most Deal Teams Are Looking in the Wrong Places

The natural instinct for dental deal sourcing is to target large metros with high population density. The problem is that these markets — New York, Los Angeles, Chicago — are also where DSO penetration is highest. Entering a market where 40–50% of practices are already platform-affiliated means you're paying premium multiples for a shrinking pool of independent targets.

The better acquisition thesis targets markets where fragmentation remains high, commercial insurance penetration is strong, and DSO presence is still minimal. These markets exist across the US — they're just not visible without systematic data.

How We Measure DSO Penetration

We use NPPES parent organization data to identify practices affiliated with a larger entity — a reliable proxy for DSO penetration that doesn't depend on self-reported data. Markets with high solo NPI ratios (individual practitioners billing under their own NPI with no parent organization) represent the unconsolidated opportunity.

The Highest-Opportunity Dental Markets

Our dental scoring model weighs three dimensions: Demand (35%), Fragmentation (35%), and Market Quality (30%). The fragmentation dimension specifically captures solo NPI ratio, HRSA dental shortage designation, and specialty mix — variables that directly predict acquisition opportunity.

The Recapitalization Tailwind

2026 is expected to be a strong seller's market for dental PE, with roughly 44+ DSOs more than five years into their hold period facing recapitalization events. These platforms need to demonstrate continued growth — which means they need to keep acquiring independent practices in new markets.

For PE firms evaluating dental roll-up opportunities, the question isn't whether there's opportunity. It's which markets to enter first, and which to avoid because the consolidation arbitrage has already been competed away.

Every healthcare PE deal starts the same way. An associate pulls up CMS.gov, downloads a data file that hasn't been cleaned since 2019, and starts building an Excel model from scratch. Two weeks later, they have something that might answer the question they started with.

This is how most mid-market PE firms doing healthcare roll-ups approach market diligence. And it works — eventually. But it's slow, inconsistent, and expensive in analyst time. More importantly, it means every deal team is solving the same problem independently, with no standardized methodology and no way to benchmark one market against another.

What PE Firms Actually Need

The question a deal team is trying to answer is simple: is this market worth entering, and if so, where do we start? What makes that question hard to answer isn't the analysis — it's the data assembly. NPPES, HRSA, CMS claims, SAMHSA, PolicyMap — each source requires different download procedures, different cleaning steps, and different domain knowledge to interpret correctly.

The firms that do this well have either hired a dedicated healthcare data analyst (a $150–200K annual cost) or they're paying a consulting firm $50–150K for a bespoke market assessment. Neither option scales to the deal volume that successful healthcare PE requires.

The Gap in the Market

Enterprise platforms like Grata (acquired by Datasite for $500M+ in 2025) and Definitive Healthcare ($40K+/year) have validated that PE firms will pay for acquisition intelligence. But both products are built for enterprise procurement cycles, not the mid-market deal team that needs a dental market assessment before Thursday's IC meeting.

The gap is a product that delivers PE-grade market intelligence — scored, ranked, actionable — at a price point below the procurement threshold and available immediately. No sales cycle, no annual commitment, no IT review.

What "PE-Grade" Actually Means

It means the scoring model is built around variables that predict acquisition success, not generic market health indicators. Solo NPI ratio — the fraction of providers billing independently with no parent organization — is a better predictor of acquisition opportunity than population density. HRSA shortage designation correlates with reimbursement favorability. Medicaid concentration predicts revenue risk through 2027–2028 federal budget changes. These aren't metrics that appear in a standard market study.

What This Looks Like in Practice

AcuiteIQ was built to answer exactly this problem. Five verticals — Behavioral Health, Dental, Home Health, IDD/Autism, and Physician Specialties — each scored at the MSA level across 400+ US markets, with acquisition target lists ready for Monday morning outreach.

One report. One-time purchase. No subscription. Delivered in minutes.

For the deal team that would otherwise spend three weeks building this analysis, the math is straightforward. For the fund that needs to evaluate five markets before the next IC cycle, the alternative to AcuiteIQ is a consulting engagement that costs more and takes longer.